ADVERSE EVENTS DURING TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE DRUG RESISTANT TUBERCULOSIS

Objective: to perform retrospective analysis of the ranges, structure, degree of severity and time of development of adverse events in tuberculosis patients with multiple drug resistance on treatment and to assess their impact on chemotherapy duration 

Results. Totally, 1387 adverse events were registered Out of 500 patients, adverse events occurred in 437 (874%) Intestinal (293 patients, 670%) and metabolic (297 patients, 680%) adverse events prevailed Each second patient developed neurological and hepatotoxic adverse events (222 (508%) and 175 (400%) respectively) Dermatological adverse events, ototoxicity, hypothyrosis, and nephrotoxicity were observed in 123 (281%), 114 (261%), 72 (165%), and 56 (128%) patients respectively 21 (48%) patients had adverse events affecting vision 14 (32%) patients suffered from peripheral neuropathy On average, one patient had adverse events affecting three systems of the host If one patient had three different types of adverse events and more, the duration of treatment made more than 700 days Each fourth MDR TB patient (2494%) had severe adverse events

Conclusions. Adverse events occurring during treatment of multiple drug resistant tuberculosis are manifested through arthralgia, intestinal and central nervous system disorders In order to prevent adverse events laboratory abnormalities and clinical manifestations are to be monitored on a regular basis

1. Vasilieva I.А., Belilovskiy E.M., Borisov S.E., Sterlikov S.А. Incidence, mortality and prevalence as indicators of tuberculosis burden in WHO regions, countries of the world and the Russian Federation. Part 1. Tuberculosis incidence and prevalence. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 6, pp. 9-21. (In Russ.)

2. Gelmanova I.E., Zemlyanaya N.А., Khon L.V., Kruk E.А., Mishustin S.P., Yanova G.V. Assessment of treatment costs for drug susceptible and drug resistant tuberculosis patients in the units of Tomsk Regional TB Services. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 3, pp. 20-27. (In Russ.)

3. Golubchikov P.N., Mishustin S.P., Zemlyanaya N.А., Tonkel T.P. Clinical management of multiple drug resistant tuberculosis: system of prevention, monitoring and management of adverse reactions to anti-tuberculosis drugs. Tuberculosis and Lung Diseases, 2014, no. 1, pp. 22-27. (In Russ.)

4. Ivanova D.А., Borisov S.E. Profile and risk factors of adverse reactions in new tuberculosis cases receiving treatment. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 6, pp. 22-29. (In Russ.)

5. Sterlikov S.А., Testov V.V., Vasilieva I.А. Treatment results of patients with multiple and extensive drug resistance registered in 2012 in the Russian Federation and worldwide. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 1, pp. 22-27. (In Russ.)

6. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. Moscow, Tver, Triada Publ., 2014. 72 p.

7. Filinyuk O.V., Felker I.G., Yanova G.V., Bujnova L.N., Kolokolova O.V. Risk factors of chemotherapy failure in multiple drug resistant tuberculosis patients. Tuberculosis and Lung Diseases, 2014, no. 1, pp. 20-26. (In Russ.)

8. Bloss E., Kuksa L., Holtz T.H., Riekstina V., Skripconoka V., Kammerer S., Leimane V. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int. J. Tuberc. Lung Dis., 2010, vol. 14, no. 3, pp. 275-278.

9. Global tuberculosis report, 2016, WHO.

10. Hoa N. B., Nhung N. V., Khanh P. H., Hai N. V., Quyen B. T. Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam // BMC Research Notes. – 2015. – № 8. – P. 809-815.

11. KapadiaVishakha K., Tripathi Sanjay B. Analysis of 63 Patients of MDR TB on DOTS Plus regimen: An LG Hospital, TB Unit // Ahmedabad Experience Gujarat Medical J. ‒ 2013. – Vol. 68. – P. 52-57.

12. Neeta P. N., Prashanth N., G. Ramaprasad, T. Gangadhar Goud, Sameena A. R. B. A study on outcome of standardized treatment in multi-drug resistance tuberculosis patients // Int. J. Community Med. Public Health. – 2016. ‒ Vol. 3, № 1. – P. 257-263.

13. US Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Bethesda, MD, USA: National Institutes of Health, National Cancer Institute, 2010.

14. Uplekar M., Weil D., Lonnroth K., Jaramillo E., Lienhardt C., Dias H. M., ... &Gilpin C. WHO's new end TB strategy // Lancet. – 2015. – Vol. 385. – P. 1799 – 1801.

15. Zhang Y., Wu S., Xia Y., Wang N., Zhou L., Wang J., Fang R., Sun F., Chen M., Zhan S. Adverse events associated with treatment of multidrug-resistant tuberculosis in China: An ambispective cohort study // Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. – 2017. ‒ Vol. 23. – P. 2348-2356.